全部所有文章

President of United BioPharma, Dr. Mei Jun Liao, is invited to the 5th Biologics World Taiwan as The Invited Speaker

 
                 

Mei Jun Liao, Ph.D.

President of United BioPharma (UBP, 6471), Mei Jun Liao, Ph.D., will join the 5th Biologics World Taiwan from March 7th to March 9th in 2017 as the invited speaker. Biologics World Taiwan is an international forum focused on the biopharmaceutical industry.

Read More
 
Dr. Liao received her Ph.D. in physical Biochemistry from Yale University and joined UBP in 2014, with extensive experience in the biopharmaceutical industry. Dr. Liao has led UBP to achieve considerable milestones. For example, UBP is launching the international phase III clinical trial for its innovative AIDS therapeutic candidate UB-421.
 
UBP processes an integrated-advanced R&D platform and many new drugs with significant market potential. Moreover, the new industrial-scale protein API facility will be completed in April this year. UBP strives to file new drug applications and expand international business and strategic alliances.
 
 
About United BioPharma (6471)
United BioPharma (UBP) was established in September 2013 as a spinoff from United Biomedical, Inc., Asia, and is strategically partnered with Formosa Plastics Group. UBP has an integrated monoclonal antibody drug development platform, and focuses on development, manufacturing, and marketing of innovative monoclonal antibody drugs and biosimilars. With a spirit of “innovation and practicality,” UBP is dedicated to addressing unmet medical needs to improve the health of mankind. For more information, please visit
https://www.ubpglobal.com/

United BioPharma Forward-Looking Statements
The information in this press release should be considered accurate only as of the date of the release. UBP has no intention of updating and specifically disclaims any duty to update the information in this press release. The press release may contain forward-looking statements involving risks and uncertainties and UBP’s actual results may differ materially from those in the forward-looking statements.
 
Contact
Victor Run-Ben Sun
Spokesperson and Vice President of Public Affairs
+886-978-067-006
PR@unitedbiopharma.com
victor.sun@unitedbiopharma.com
回上頁